Results 161 to 170 of about 117,562 (243)

Мiryachit: A Culture‐Specific Startle Syndrome in the Saami People

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Miryachit is perhaps the most complex and least understood of the culture‐specific startle syndromes that include latah and the jumping Frenchmen of Maine. Objectives We carried out a field study to evaluate startle‐induced paroxysms in the Saami to determine if it is still endemic and, if so, to contrast it with the available ...
Marianna Selikhova   +3 more
wiley   +1 more source

Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is a largely unmet need. Objectives Mesdopetam is a novel small molecule dopamine D3 receptor antagonist aimed for the treatment of levodopa‐induced dyskinesia.
Angelo Antonini   +6 more
wiley   +1 more source

Simultaneous Nonmotor Symptoms Do Not Affect General Validity but Interpretation of the Parkinson's Disease Motor Diary

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Motor fluctuations are routinely documented using the Parkinson's disease (PD) home diary. However, the validity of this diary when compared to clinical observers is limited. Objective This study disassembled the effects of nonmotor symptoms (NMS) on inter‐method agreement between the PD home motor diary and clinical observers ...
Hampus Andersson   +6 more
wiley   +1 more source

Microneedle interventional therapy combined with cervical spine manipulation for cervicogenic dizziness [PDF]

open access: yes, 2018
Duan, Junfeng   +10 more
core   +1 more source

Editorial: Vestibular migraine. [PDF]

open access: yesFront Neurol
Espinosa-Sanchez JM, Lin CC.
europepmc   +1 more source

NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy

open access: yesMovement Disorders, EarlyView.
Abstract Background Levodopa‐induced dyskinesia (LID) in Parkinson's disease (PD) is associated with ‘false neurotransmitter’ release of dopamine from serotonin (5‐HT) neurons. NLX‐112 is a first‐in‐class, highly selective 5‐HT1A receptor agonist which counteracts LIDs in experimental PD models.
Per Svenningsson   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy